Clinical and biological significance of RAS mutations in multiple myeloma

被引：0
|
作者：
W J Chng
N Gonzalez-Paz
T Price-Troska
S Jacobus
S V Rajkumar
M M Oken
R A Kyle
K J Henderson
S Van Wier
P Greipp
B Van Ness
R Fonseca
机构：
[1] Mayo Clinic,Department of Haematology
[2] Mayo Clinic,Oncology
[3] Eastern Cooperative Oncology Group Statistical Center,Division of Haemtology
[4] Dana Faber Cancer Institute,Department of Oncology
[5] North Memorial Cancer Center,Department of genetics
[6] cell biology and development,Department of Medicine
[7] University of Minnesota,Department of Haematology
[8] Yong Loo Lin School of Medicine,Oncology
[9] National University of Singapore,undefined
[10] National University Hospital,undefined
来源：
Leukemia | 2008年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2280 / 2284
页数：4
相关论文
共 50 条
  • [1] Clinical and biological significance of RAS mutations in multiple myeloma
    Chng, W. J.
    Gonzalez-Paz, N.
    Price-Troska, T.
    Jacobus, S.
    Rajkumar, S. V.
    Oken, M. M.
    Kyle, R. A.
    Henderson, K. J.
    Van Wier, S.
    Greipp, P.
    Van Ness, B.
    Fonseca, R.
    LEUKEMIA, 2008, 22 (12) : 2280 - 2284
  • [2] Activating Ras mutations in multiple myeloma
    Norton, JD
    Rothwell, DG
    Kalakonda, N
    BLOOD, 2002, 100 (03) : 1103 - 1103
  • [3] RAS mutations - for better or for worse in multiple myeloma?
    Leich, Ellen
    Steinbrunn, Torsten
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 8 - 9
  • [4] The biological significance of histone modifiers in multiple myeloma: clinical applications
    Hiroto Ohguchi
    Teru Hideshima
    Kenneth C. Anderson
    Blood Cancer Journal, 8
  • [5] The biological significance of histone modifiers in multiple myeloma: clinical applications
    Ohguchi, Hiroto
    Hideshima, Teru
    Anderson, Kenneth C.
    BLOOD CANCER JOURNAL, 2018, 8
  • [6] Implications of N-ras and K-ras mutations in clinical outcome and the biology of multiple myeloma (MM).
    Fonseca, R
    Price-Troska, T
    Blood, E
    Rajkumar, SV
    Oken, MM
    Kay, NE
    Kyle, RA
    Van Wier, SA
    Henderson, KJ
    Greipp, PR
    Van Ness, BG
    BLOOD, 2003, 102 (11) : 36A - 36A
  • [7] Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance
    Paiva, Bruno
    Puig, Noemi
    Vidriales, Maria-Belen
    Carmen Gutierrez, Norma
    Hernandez, Miguel T.
    Rosinol, Laura
    Ocio, Enrique M.
    Oriol, Albert
    Asuncion Echeveste, Mara
    Gonzalez, Yolanda
    Gironella, Mercedes
    Prieto, Julio
    Jose Moreno, Maria
    Giraldo, Pilar
    Palomera, Luis
    Aoiz, Intza
    Blade, Joan
    Jose Lahuerta, Juan
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    BLOOD, 2014, 124 (21)
  • [8] Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
    Hiroto Ohguchi
    Teru Hideshima
    Kenneth C. Anderson
    Blood Cancer Journal, 11
  • [9] RAS ONCOGENE MUTATIONS IN KOREAN PATIENTS WITH MULTIPLE-MYELOMA
    KIM, JH
    KIM, SY
    YOON, HJ
    CHO, KS
    BLOOD, 1994, 84 (10) : A656 - A656
  • [10] RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies
    Martín, P
    Santón, A
    García-Cosío, M
    Bellas, C
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (04) : 1023 - 1028
12345